Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 2, 2006, Pages 477-482

  Anscher, Mitchell S ^a   Garst, Jennifer ^a   Marks, Lawrence B ^a   Larrier, Nicole ^a   Dunphy, Frank ^a   Herndon II, James E ^a   Clough, Robert ^a   Marino, Christine ^a   Vujaskovic, Zeljko ^a   Zhou, Sumin ^a   Dewhirst, Mark W ^a   Shafman, Timothy D ^a   Crawford, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Complications; Cytokines; Non small cell lung cancer; Thalidomide

Indexed keywords

CHEMOTHERAPY; DOSIMETRY; MEDICAL PROBLEMS; PATIENT MONITORING; PULMONARY DISEASES; RADIOTHERAPY;

ANTICYTOKINE AGENTS; CYTOKINES; NON-SMALL-CELL LUNG CANCER; THALIDOMIDE;

DRUG THERAPY;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR; BILIRUBIN; CREATININE; CYTOKINE; LORAZEPAM; NAVELBINE; PROCHLORPERAZINE MALEATE; THALIDOMIDE; THIETHYLPERAZINE MALEATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; WARFARIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRADYCARDIA; BRAIN EMBOLISM; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CONSTIPATION; DOSE CALCULATION; DRUG DOSE REDUCTION; ESOPHAGUS DISEASE; FEMALE; GASTRITIS; HUMAN; HYPOTHYROIDISM; INOPERABLE CANCER; KARNOFSKY PERFORMANCE STATUS; LIFE EXPECTANCY; LUNG EMBOLISM; LUNG FUNCTION; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NATIONAL CANCER INSTITUTE COMMON TOXICITY CRITERIA; NEUROTOXICITY; PRIORITY JOURNAL; RADIATION INJURY; RASH; SCORING SYSTEM; SKIN TOXICITY; STROKE; THROMBOSIS; THROMBOSIS PREVENTION; VISUAL DISORDER;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; THALIDOMIDE; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINBLASTINE;

EID: 33748299333     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.031     Document Type: Article

References (39)

1. Carmel R.J., and Kaplan H.S. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer 37 (1976) 2813-2825
2. Lingos T.I., Recht A., Vicini F., et al. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21 (1991) 355-360
3. Martel M., Ten Haken R., Hazuka M., et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 28 (1994) 575-581
4. Morgan G.W., Freeman A.P., McLean R.G., et al. Late cardiac, thyroid, and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 11 (1985) 1925-1931
5. Penn C.R., and Hope-Stone H.F. The role of radiotherapy in the management of malignant thymoma. Br J Surg 59 (1972) 533-539
6. Roach M., Gandara D., You H., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
7. Rothwell R.I., Kelly S.A., and Joslin C.A. Radiation pneumonitis in patients treated for breast cancer. Radiother Oncol 4 (1985) 9-14
8. Tarbell N.J., Thompson L., and Mauch P. Thoracic irradiation in Hodgkin's disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 18 (1990) 275-281
9. Curran Jr. W.J., Moldofsky P.J., and Solin L.J. Observations on the predictive value of perfusion lung scans on post-irradiation pulmonary function among 210 patients with bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 24 (1992) 31-36
10. Kimsey F.C., Mendenhall N.P., Ewald L.M., et al. Is radiation treatment volume a predictor for acute or late effect on pulmonary function?. A prospective study of patients treated with breast-conserving surgery and postoperative irradiation. Cancer 73 (1994) 2549-2555
11. Rubenstein J.H., Richter M.P., Moldofsky P.J., et al. Prospective prediction of post-radiation therapy lung function using quantitative lung scans and pulmonary function testing. Int J Radiat Oncol Biol Phys 15 (1988) 83-87
12. Anscher M.S., Chen L., Rabbani Z., et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 255-259
13. Robbins M.E., and Diz D.I. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 64 (2006) 6-12
14. Li Y.-Q., Ballinger J., Nordal R., et al. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 61 (2001) 3348-3354
15. Schroeder T., Rabbani Z.N., Samulski T.V., et al. Diffusion-limited hypoxia is associated with chronic radiation-induced lung injury. [Abstract]. Int J Radiat Oncol Biol Phys 57 (2003) S323
16. Vujaskovic Z., Anscher M.S., Feng Q.F., et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50 (2001) 851-855
17. Yagyu T., Kobayashi H., Matsuzaki H., et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 90 (2005) 3017-3021
18. Zorat F., Shetty V., Dutt D., et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115 (2001) 881-894
19. Garst J., Shafman T., Campagna L., et al. A phase II study of concurrent multidose Vinorelbine with definitive radiation therapy for inoperable stage III non-small cell lung cancer. [Abstract]. Proc ASCO 20 (2001) 343a
20. Ettinger D.S. An overview of eastern cooperative oncology group stage III non-small cell lung cancer studies. Semin Oncol 32 (2005) S109-S110
21. Merchant J., Kim K., Mehta M., et al. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non-small cell lung cancer. Clinical Lung Cancer 2 (2000) 48-52
22. Behrens R.J., Gulley J.L., and Dahut W.L. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10 (2003) 228-232
23. Chang S.M., Lamborn K.R., Malec M., et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60 (2004) 353-357
24. Kerst J.M., Bex A., Mallo H., et al. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 54 (2005) 926-931
25. Sampaio E.P., Kaplan G., Miranda A., et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168 (1993) 408-414
26. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
27. Gordon J.N., Trebble T.M., Ellis R.D., et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54 (2005) 540-545
28. Dmoszynska A., Bojarska-Junak A., Domanski D., et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 43 (2002) 401-406
29. Jin S.H., Kim T.I., Han D.S., et al. Thalidomide suppresses the interleukin 1beta-induced NFkappaB signaling pathway in colon cancer cells. Ann N Y Acad Sci 973 (2002) 414-418
30. Settles B., Stevenson A., Wilson K., et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol 47 (2001) 1105-1114
31. Fujita J., Mestre J.R., Zeldis J.B., et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res 7 (2001) 3349-3355
32. Hallahan D.E., Geng L., and Shyr Y. Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst 94 (2002) 733-741
33. Franko A.J., Sharplin J., Ghahary A., et al. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res 147 (1997) 245-256
34. Epperly M., Travis E., Sikora C., et al. Magnesium superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: modulation of irradiation-induced mRNA for IL-1, TNF-a, and TGF-β correlates with delay of organizing alveolitis/fibrosis. Blood Bone Marrow Transplant 5 (1999) 204-214
35. Brach M.A., Hass R., Sherman M.L., et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 88 (1991) 691-695
36. Chen Y., Rubin P., Williams J., et al. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 49 (2001) 641-648
37. Vujaskovic Z., Marks L., and Anscher M. The physical parameters and molecular events associated with radiation-induced lung toxicity. Sem Radiat Oncol 10 (2000) 296-307
38. Haslett P.A., Klausner J.D., Makonkawkeyoon S., et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 15 (1999) 1169-1179
39. Haslett P.A., Corral L.G., Albert M., et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187 (1998) 1885-1892